ALMS
Alumis Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +15.4% ·
share flow +10.0% ·
net new positions +13.3%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 75 | 0 | 42.52M | $1.19B | +6 | −6 |
| Q1 2026 | 78 | +19 | 38.58M | $847.29M | +25 | −6 |
| Q4 2025 | 58 | +2 | 18.95M | $184.97M | +2 | — |
| Q3 2025 | 15 | +2 | 13.24M | $52.83M | +2 | — |
| Q2 2025 | 10 | +3 | 10.75M | $32.25M | +5 | −2 |
| Q1 2025 | 4 | -1 | 688.93K | $4.23M | +1 | −2 |
| Q4 2024 | 5 | +1 | 715.32K | $5.62M | +1 | — |
| Q3 2024 | 3 | -1 | 573.51K | $6.13M | +1 | −2 |
| Q2 2024 | 4 | — | 543.74K | $7.23M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 4.19M | +0.4% | $16.73M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 2 | The Vanguard Group ✦ (passive) | 4.03M | +18.4% | $16.08M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | Geode Capital Management ✦ (passive) | 1.39M | +19.3% | $5.56M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 1.10M | -0.7% | $4.40M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | JPMorgan Chase ✦ | 537.33K | — | $2.14M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 6 | Goldman Sachs Group ✦ | 417.08K | — | $1.66M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 339.25K | +216.8% | $1.35M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 332.41K | — | $1.33M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 9 | Millennium Management ✦ | 317.03K | -36.7% | $1.26M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 165.50K | New | $660,357 | 0.0% | New | 1 | SEC ↗ ×3 |
| 11 | Renaissance Technologies ✦ | 151.57K | -33.2% | $604,756 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 140.92K | +439.6% | $562,258 | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 13 | Two Sigma Investments ✦ | 86.08K | New | $343,475 | 0.0% | New | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 28.27K | 0.0% | $113,000 | 0.0% | Held | 2 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 6.93K | +43.2% | $27,655 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $660,357 | 0.0% |
| Two Sigma Investments | $343,475 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 194 holders, 98.56M shares, $2.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 273.29K sh @ 10.63 · $2.90M
Director · 273.29K sh @ 10.63 · $2.90M
Director · 220.07K sh @ 11.17 · $2.46M
Director · 220.07K sh @ 11.17 · $2.46M
Open-market sales (S)
Director · 48.07K sh · $507,019
Director · 48.06K sh · $507,009
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
3.5% of class · View original SEC filing ↗
12.3% of class · View original SEC filing ↗